

Press Release*For Immediate Release***Yicura BioMed Announces Publication of Phase I Data for ICVAX in
Top International Journal**

*Prestigious Journal Publication Validates
Rigorous Standards and Highly Encouraging Findings*

(Hong Kong, July 24, 2026) – Yicura BioMed ("**Yicura**") (formerly known as Immuno Cure BioTech), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce the [publication of the Phase I clinical trial data](#) for its HIV therapeutic DNA vaccine, ICVAX®, in the peer-reviewed international scientific journal the *Journal of Infectious Diseases* ("**JID**").

The JID is a prestigious global journal bridging basic microbiology and clinical research. Specializing in immunology, disease mechanisms, animal models, and vaccine innovation, it is a premier destination for preclinical and early-phase human trial papers. The JID is the flagship journal of the Infectious Diseases Society of America ("**IDSA**"), published by Oxford University Press, and stands as a long-established core journal in the field of infectious diseases. Yicura's publication thus underscores the rigorous scientific standards and highly encouraging nature of the data, representing a significant milestone in the development of HIV therapies.

The randomized, double-blind, placebo-controlled, dose-escalation Phase I clinical trial (ClinicalTrials.gov identifier: NCT06253533) evaluated the safety, maximum tolerated dose, and immunogenicity of ICVAX®. Approved by the National Medical Products Administration ("**NMPA**") and conducted at the Shenzhen Third People's Hospital, the study enrolled 45 clinically stable HIV-1-infected participants whose viral replication was well-suppressed by antiretroviral therapy.

All 45 participants completed their scheduled follow-up visits. ICVAX® demonstrated a favourable safety profile, with all treatment-related adverse events categorized as mild. On the immunogenicity front, recipients exhibited promising T-cell responses, while

notably, a large majority of participants in the optimal dose cohort showed a greater than twofold increase in T-cell activity.

Having successfully met all primary and secondary endpoints, the Phase I data has now been published in the JID. Yicura has also submitted the data to regulatory authorities to support advancing ICVAX® into a Phase II efficacy clinical trial, which is scheduled to be carried out in the second half of this year.

In May 2026, the research facility for ICVAX®, established under the Center of International Innovation for Technology and Science (“**CIITS**”), officially inaugurated in Hetao, Shenzhen. Leveraging its platform advantages in resource integration, innovation incubation, and technology transfer services, CIITS fully supports the research facility in building an efficient and standardized viral load and immune response monitoring system. This initiative will strongly propel the clinical translation and commercialization process of ICVAX®, providing vital support for its ongoing clinical trials and industrial development.

Prof. Zhiwei CHEN, the Principal Scientific Advisor of Yicura, stated, “The publication of our Phase I data validates the scientific rigor behind ICVAX®. The ability of ICVAX® to trigger strong immune responses and activate protective T cells confirms its potential to train the immune system to fight HIV effectively. An important step forward in shifting from bone marrow transplantation to immunotherapy for a functional cure for AIDS.”

Dr. Xia JIN, CEO of Yicura said, “Meeting all primary and secondary endpoints is a monumental milestone for Yicura. These results confirm ICVAX® is safe and well tolerated, providing compelling early evidence to move beyond HIV suppression toward a functional cure. We look forward to advancing ICVAX® into its next clinical stage, with support from CIITS to accelerate our R&D efforts.”

###

About the Journal of Infectious Diseases (“JID”)



The Journal of Infectious Diseases is a peer-reviewed, biweekly medical journal published by Oxford University Press for the Infectious Diseases Society of America. The publication focuses on research surrounding the pathogenesis, diagnosis, and treatment of infectious diseases, their causative microbes, and related immune system disorders.

To learn more about the JID, please visit: <https://academic.oup.com/jid>

About Yicura (formerly Immuno Cure)

Yicura is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti- $\Delta 42PD1$ Antibody platforms.

To learn more about Yicura, please visit: www.yicura.hk

For media enquiries, please contact:

Yicura

Ms. Carol CHUNG

Email: carolchung@yicura.hk

Yicura

Dr. Anthony CHEUNG

Email: anthonycheung@yicura.hk